Symphony Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://www.stockscans.in/document/zrb33r8cwgnr9ovbzkckruee.pdf

Key Takeaways


The Summer Shock: What Happened and What It Means

Achal Bakeri: "The US tariffs are an evolving situation. Every day, it's something different. So we are not holding our breath about what is going to happen."

The Non-Cooler Hedge: All-Season and Counter-Seasonal Products

Amit Kumar: "So these new categories that we are talking about i.e. the tower fan, the kitchen cooling fan, the LSV also for that matter if I look at last 3 - 4 years, they are clearly giving us a 50%+ kind of CAGR and hence creating a key part of the growth portfolio that we are building."

International Subsidiaries: Restructuring and Potential Monetization

IMPCO Mexico

Symphony Australia

Monetization process

Achal Bakeri: "So what we believe internally is that we are at the bottom of that hockey stick curve. It's taken a long time to get there or to get to the point where you sort of at the beginning of the up cycle of the hockey stick curve, but we believe that's where we are."

Channel Inventory: The Overhang That Will Linger


Exports and the US Opportunity


BLDC, Product Investment and Capital Allocation

Nrupesh Shah: "And unlike other brands were in BLDC fan, despite that top line growth, they keep on registering losses, we are having and we are going to grow with profitability."

Guidance & Commitments

CommitmentSpecificsTimeline
GSK China loan repaymentOutstanding ~₹26 crores fully repaid; ~₹22 crores mostly in current quarter from IPR proceeds, remainder from internal accrualBy end of FY26
Channel inventory normalizationHigh channel inventory clears only when tertiary sales beginCloser to next summer season
Water heater pan-India presenceGradual rollout from current limited South India presence to pan-India and modern retail~1 year from now
IMPCO / Australia monetizationTransaction possible; early-stage NDA interest from international buyersEnd of FY26 or early FY27
No further acquisitionsCategorical commitment: no international or domestic acquisitions; export model will follow Brazil patternOngoing
US retail ordersAll major US retail chains have shortlisted models; large orders being finalized for upcoming summerAhead of summer '26

Key Metrics

MetricQ1 FY26
Standalone revenue₹229 cr, down from ₹373 cr YoY
Standalone PAT₹37 cr, down from ₹69 cr YoY
Exceptional gain (Pathways recovery)~₹5 cr
Consolidated revenue (continuing ops)₹251 cr
Consolidated PAT (continuing ops)₹39 cr, PAT margin 15.4%
Consolidated revenue (discontinuing ops)₹99 cr
Consolidated PAT (discontinuing ops)₹3 cr, EBITDA margin 12.1%
Trailing 12 months revenue₹1,038 cr, vs ₹996 cr in prior 12 months
Trailing 12 months EBITDA₹229 cr, almost flat
Trailing 12 months PBT before exceptional item₹283 cr, up from ₹275 cr
Trailing 12 months ROCEInfinite; RONW 18%
Treasury₹363 cr as on June 30, 2025
Interim dividend₹1 per share, totalling ~₹7 cr
Final dividend₹8 per share
Last year total payout84% of consolidated PAT
All-season and counter-seasonal product sales share (trailing 12 months)~25% of Symphony India sales, up from less than 10% earlier
GSK China IPR transaction to IMPCO MexicoUSD 5.2 mn (~₹44 cr); first tranche ₹22 cr concluded in June 2025 quarter
GSK China outstanding loan to Symphony India~₹26 cr, down from peak of ~₹60 cr in May 2024
US sales growthSignificantly higher YoY and QoQ